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Proteomes are signiﬁcantly more complex than genomes
and transcriptomes due to protein processing and extensive
post-translational modiﬁcation (PTM)of proteins. Hundreds
of diﬀerent modiﬁcations exist. Release 66 of the RESID
database
1 (http://www.ebi.ac.uk/RESID/) contains 559 dif-
ferent modiﬁcations, including small chemical modiﬁcations
such as phosphorylation, acetylation, and methylation and mod-
iﬁcation by small proteins, including ubiquitin and ubiquitin-
like (UBL) proteins that are covalently coupled to proteins to
regulate their activity. A wide variety of cellular processes are
regulated by these reversible modiﬁcations, including transcrip-
tion, replication, cell-cycle progression, and responses to DNA
damage.
Protein modiﬁcations have been studied for many years at the
level of single target proteins, but currently available technologies
enable proteome-wide studies of these modiﬁcations by mass
spectrometry (MS).
2,3 Powerful proteomics tools are available to
study phosphorylation and acetylation at a systems-wide level in a
site-speciﬁc manner. It is more challenging to study ubiquitin
targets and targets for ubiquitin-like proteins at a proteome-wide
level in a site-speciﬁc manner due to the relatively large size of
thesemodiﬁcations,buthundredsofpotentialtargetproteinshave
been uncovered over the past eight years, mainly in a non-site-
speciﬁc manner. This review is focused on uncovering signaling
networksforubiquitinandubiquitin-likeproteinsbymassspectro-
metryandhighlightsthesite-speciﬁcstudiespublishedin2010and
2011. Site-speciﬁc methodologies will likely have a major impact
ontheubiquitinﬁeldinthenearfuture.Themethodology,results,
challenges, pitfalls, crosstalk with other PTMs, and future direc-
tions are discussed in this review.
Received: May 27, 20117924 dx.doi.org/10.1021/cr200187e |Chem. Rev. 2011, 111, 7923–7940
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1.1. Ubiquitin and Ubiquitin-like Proteins
Ubiquitin was ﬁrst discovered in the mid-1970s, and the 2004
NobelPrizeinChemistrywasawardedforthisﬁnding.Ubiquitin
is a 76 amino acid protein that is highly conserved from yeast to
plants and mammals. Many ubiquitin-like proteins have been
uncovered, including Nedd8, small ubiquitin-like modiﬁer 1
(SUMO-1), SUMO-2, SUMO-3, FUBI, HUB1, ISG15, FAT10,
URM1, UFM1, Atg12, and Atg8. Ubiquitin-like proteins are also
found in prokaryotes and archaea; PUPs are prokaryotic ubiqui-
tin-like proteins, and SAMPs are ubiquitin-like small archaeal
modiﬁer proteins. Despite limited sequence homology of some




These small proteins are covalently coupled to target proteins
via isopeptide bonds between C-terminal diglycine motifs and ε-
amino groups in lysines of target proteins using an enzymatic
cascadethat consistsof anE1 enzyme,
10 anactivatorof ubiquitin
and UBLs, an E2 enzyme,




dedicated to ubiquitin, 1 shared between ubiquitin and the UBL
FAT10, and 6 dedicated to other UBLs) and 35 active E2
enzymes (including 28 dedicated to ubiquitin, 3 shared between
ubiquitin and the UBL ISG15, 3 dedicated to other UBLs,
and 1 putative E2).
12 Ubiquitin E3 enzymes are subdivided into
HECT-type E3 enzymes (homology to E6AP carboxyl terminus)
14
and RING-type E3 enzymes (really interesting new gene).
15
HECT-type E3 enzymes form thioesters with ubiquitin, whereas
RING-typeE3enzymeslackcatalyticcysteines.Over600human
genes encode components of RING-based E3 ligases.
15
Ubiquitylation is a reversible process; nearly 100 diﬀerent deubi-
quitylating enzymes (Dubs) are responsible for removing ubiquitin
from target proteins in humans and for disassembling ubiquitin
chains.
16 19 These proteases belong to six diﬀerent families, includ-
ing ﬁve families of cysteine proteases: ubiquitin-speciﬁc proteases
(USPs), herpesvirus tegument USPs (htUSPs), ubiquitin
C-terminal hydrolases (UCHs), ovarian tumor proteases
(OTUs), and the family of Josephins. The sixth family of
ubiquitin proteases are the JAB1/MPN/MOV34 proteases
(JAMMs), which are Zn
2+ metalloproteases.
Seven internal lysines are present in ubiquitin that are used
for chain formation and diﬀerent chain topologies, including






22,23 In addition to covalent interactions, noncovalent
interactions contribute to the complexity of signaling. At least
20 diﬀerent types of domains have been identiﬁed in ubiquitin
binding proteins (UBP) that interact with ubiquitin in a non-
covalent manner
24,25 to regulate the fate of ubiquitylated
proteins.
1.2. Quantitative Proteomics
Methods such as stable isotope labeling by amino acids in
cell culture (SILAC),




are powerful tools that enable quantitative proteomics studies.
Quantiﬁcation can even be performed label-free.
31 SILAC tech-
nology employs stable isotopic variants of amino acids for
metabolic labeling of endogenous proteins and subsequent
quantiﬁcation.
32 Labeling can also be performed postharvesting
using chemical methods such as iTRAQ.
28 Labeled marker
peptides are used for AQUA, and these peptides are spiked at
known concentrations to enable absolute quantiﬁcations.
29,30
Quantitative proteomics is particularly useful for studying ubi-
quitylation dynamics in response to diﬀerent stimuli. Further-
more, control cell populations can be included in experiments to
distinguish between ubiquitin target proteins and contaminants.




of the E1 enzyme in an adenosine 50-triphosphate-dependent manner to form a thioester. Subsequently, transfer to the active site cysteine in an E2
enzymeoccurs,andanovelthioesterisformed.WiththehelpofE3enzymes,ubiquitiniscoupledtolysinesintargetproteinsviaisopeptidebonds,andin
a subsequent optional step, ubiquitin chains can be formed. Speciﬁc proteases remove ubiquitin from target proteins, and free ubiquitin becomes
available for novel rounds of conjugation.7925 dx.doi.org/10.1021/cr200187e |Chem. Rev. 2011, 111, 7923–7940
Chemical Reviews REVIEW
cell populations are diﬀerentially labeled using isotopic variants
of arginine and lysine and cells are treated with speciﬁc stimuli.
33
Cells are lysed in a denaturing buﬀer to inactivate proteases,
and ubiquitin conjugates or UBL conjugates are subsequently
puriﬁed.Aftertrypsindigestionandanalysisofthedigestedpeptides
by mass spectrometry, database searches enable protein identiﬁca-
tion. Speciﬁc software is employed to determine ratios between
isotopic variants of peptides to identify target proteins that are
aﬀected by speciﬁc treatments and to distinguish between target
proteins and contaminants.
34 36
1.3. Setting the Scenery: Mass Spectrometry Based Investi-
gation of Phosphorylation and Acetylation
Mass spectrometry based proteomics studies of phosphoryla-
tionandacetylationareparticularlysuccessfulandprovide useful
frameworks for proteomics studies of other PTMs, including
ubiquitylation.
3,37 Critical tools are available that enable the
puriﬁcation of modiﬁed peptides and proteins, and these modiﬁca-
tionscanbeidentiﬁedinasite-speciﬁcmanner.Phosphopeptides
are puriﬁed using Fe
3+ immobilized metal aﬃnity chromatography
(IMAC) and TiO2.
37 39 The copuriﬁcation of acidic peptides
can be circumvented by including 2,5-dihydroxybenzoic acid
(DHB) in the buﬀers as a competitive agent.
40 Phosphorylated
tyrosinecontainingproteinsandpeptidescanbeenrichedusinga
speciﬁc antibody directed against phosphotyrosines.
41 Alterna-
tively, Src homology 2 (SH2) domains that normally bind phos-
photyrosines in a sequence-speciﬁc manner can be used as traps
to enrich tyrosine-phosphorylated proteins.
42
In 2006, a key paper was published on phosphorylation
dynamics in response to epidermal growth factor (EGF).
43 This
study combined SILAC technology
27 with phosphopeptide
enrichment to identify EGF-regulated phosphorylation events
at an until then unprecedented scale of 6600 events. Diﬀerent
clusters of kinetic proﬁles were identiﬁed, including signal
initiators, intermediate stimulators, late stimulators, terminal
eﬀectors, and early and late negative regulators. The relative
frequency of phosphorylation of tyrosine, threonine, and serine
residues was 1.8%, 11.8%, and 86.4%, respectively, compared to
initial estimates of 0.05%, 10%, and 90%, respectively, by Hunter
and Sefton,
44 thus a marked increase in tyrosine phosphoryla-
tion. Another example of the power of proteomics was the
identiﬁcation of 3067 phosphorylation sites during embryonic
stem celldiﬀerentiation.
45More recently, over 20000 phosphor-
ylation events were uncovered during cell-cycle progression
46
and nearly 36000 phosphorylation sites were detected in
diﬀerent mouse organs, revealing tissue-speciﬁc phosphor-
ylation patterns.
47
Studying acetylation is more challenging. The available poly-
clonalantibodyisalimitedresourceandhasbeenusedtoidentify
over 3600 lysine acetylation sites in 1750 proteins.
48 SILAC was
employed to identify changes in the acetylated proteome in
response to the deacetylase inhibitors suberoylanilide hydroxa-
mic acid and MS-275. This study showed that lysine acetylation
preferentially targets large protein complexes involved in many
diﬀerent cellular processes, including cell-cycle progression,
chromatin remodeling, pre-mRNA splicing, and nuclear trans-
port.Monoclonalantibodiesthatrecognizeacetylatedlysinesare
also currently available.
2. UBIQUITIN AND UBIQUITIN-LIKE PROTEIN PURIFI-
CATION APPROACHES
Major approaches to purify ubiquitin and ubiquitin-like pro-
teins include the use of epitope-tagged forms of these small
protein modiﬁers, speciﬁc traps, and speciﬁc antibodies that
enable the puriﬁcation of endogenous ubiquitin and ubiquitin-
like proteins (Figure 2). These approaches can be regarded as
complementary methods with speciﬁc advantages and disadvan-
tagesthatarediscussedbelow.Importantly,puriﬁcationmethods
have to deal with the challenge of Dubs and UBL proteases to
avoid deconjugation from target proteins.
2.1. Epitope-Tagged Ubiquitin and Ubiquitin-like Proteins
Short histidine stretches (hexamer to octamer) have tradi-
tionally been very useful epitope tags for ubiquitin and UBL
enrichment since they interact with metal ions, including Ni
2+
and Co
2+, in strongly denaturing buﬀers such as 8 M urea and
6 M guanidinium hydrochloride that inactivate Dubs and UBL
proteases.
49 In addition, this methodology also prevents the
copuriﬁcation of noncovalent ubiquitin- and UBL-interacting
proteins. Subsequent analysis of puriﬁed conjugates by immuno-
blotting has extensively been used in the ﬁeld to show the
modiﬁcation of exogenous and endogenous target proteins.
Thesetagscanalsobeusedforproteomicsapproaches;however,
proteins that contain endogenous histidine stretches will be
copuriﬁed.
Other useful epitope tags include the Myc-tag, HA-tag, and
FLAG-tag, but the puriﬁcation of tagged proteins is more
challenging in denaturing buﬀers. Lysates can be prepared in
sodium dodecyl sulfate (SDS)-containing buﬀers to inactivate
proteases, but need to be diluted in milder buﬀers to avoid the
Figure 2. Ubiquitin puriﬁcation strategies. Three strategies are available to purify ubiquitin. The ﬁrst strategy employs epitope-tagged ubiquitin that is
attached to target proteins. These tags are used to purify ubiquitin. The second strategy makes use of anti-ubiquitin antibodies to purify endogenous
ubiquitin. The third strategy uses ubiquitin traps that consist ofepitope-tagged proteins containing one or more ubiquitin interaction motifs (UIMs) to
enrich for endogenous ubiquitin.7926 dx.doi.org/10.1021/cr200187e |Chem. Rev. 2011, 111, 7923–7940
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denaturation of the anti-tag antibodies. This could cause refold-
ing of proteins and potentially allows noncovalent interactions
to occur. Nevertheless, puriﬁed fractions are relatively pure.
Tandem aﬃnity puriﬁcation (TAP) strategies include the tradi-
tional TAP-tag consisting of a protein A domain and a calmo-
dulin binding domain separated by a tobacco etch virus (TEV)
cleavage site.
50,51 Alternatively, smaller tandem tags could be
employed. Tandem tag strategies are used to obtain very pure
fractions, but the ﬁnal yields can be suboptimal. Lysates are also
prepared in SDS-containing buﬀers, and dilution is needed to
allow puriﬁcation.
Another interesting strategy is the use of peptide stretches at
the N-terminus of ubiquitin and UBL proteins that can be
biotinylatedandsubsequentlypuriﬁedusingavidinorstreptavidin
resins.
52,53 Since the biotin streptavidin interaction is very
strong, denaturing conditions can be used for puriﬁcation.
However, endogenous proteins are frequently biotinylated in
cells and are copuriﬁed. A major advantage of the use of epitope-
tagged ubiquitin and UBL proteins is that these methods are
unlikely to discriminate between diﬀerent types of ubiquitin
chains and between mono- and polyubiquitylation.
2.2. Traps Based on Ubiquitin- and Ubiquitin-like Binding
Domains
As stated earlier, the ubiquitin system includes an extensive
family of noncovalent ubiquitin interactors that bind ubiquity-
lated proteins via at least 20 diﬀerent types of ubiquitin interac-
tion motifs.
24,25,54 56 These ubiquitin binding domains are used
in the ﬁeld to create traps to purify endogenous ubiquitin and
UBL proteins, enabling the use of primary cells and tissues
and patient material that cannot be studied by epitope tagging
based methods. Capturing the full ubiquitylated proteome by
ubiquitin traps is challenging due to potential preferences for




Similar to the puriﬁcation of proteins that are acetylated on
lysine residues or phosphorylated on tyrosine residues, speciﬁc
antibodies can be used to purify ubiquitin and UBL proteins.
Since ubiquitin is highly conserved from yeast to humans,
recombinant ubiquitin isasuboptimal antigen,anditistherefore
diﬃcult to generate high-aﬃnity anti-ubiquitin antibodies. Con-
sequently, this results in a relatively low yield of immunopreci-
pitates. A tool that enables site-speciﬁc identiﬁcation of ubiquitin
targetproteinsisamonoclonalantibodythatenrichesforpeptides
containing lysine residues modiﬁed by diglycine.
57
2.4. Challenges and Pitfalls
Currently availablemethodologies harbor therisk of copurify-
ing noncovalent ubiquitin interactors, particularly when using
partly renatured lysates. Furthermore, it is important to discri-
minate between speciﬁcally puriﬁed proteins and contaminants.
Quantitative proteomics experiments that include control pools
of cells could be used to discriminate between ubiquitylated
proteins and contaminants. When using aﬃnity tags, the size of
the tag could potentially inﬂuence the conjugation and deconju-
gation rates of the tagged proteins. Similar to acetylation and
phosphorylation, site-speciﬁc detection of modiﬁed residues in
target proteins would be the most rigorous method to unequi-
vocally identify modiﬁed proteins, but this is still challenging.
A critical aspect of the methodology is the inactivation of
ubiquitin and UBL proteases. Most of these proteases are
cysteine proteases; therefore, iodoacetamide has extensively
been used in the past. However, the use of iodoacetamide is
not recommended since iodoacetamide adducts on lysine resi-
dues have exactly the same mass shift as the diglycine tryptic
fragments of ubiquitin: 114.043 Da. These artifacts are particu-
larly eﬃciently produced at higher temperatures, but are not
detected at 21 C
58 and can also be avoided by using chloroa-
cetamide instead of iodoacetamide.
59
Unfortunately, the mass of the diglycine fragment of 114.043
Da is also indistinguishable from the mass of Asn, and this could
lead to false-positive assignments.
60 In contrast, the monoisoto-
pic mass of 79.966 Da for phosphorylation is unique, thus
avoiding confusion with other amino acids. In addition to the
diglycine fragment, a larger ubiquitylation remnant of 383.228
Da corresponding to LRGG has been observed.
60,61 It could be
helpful to use this larger fragment also for database searches to
identify ubiquitylation events. One group has reported that
trypsinalsodirectlycleavesC-terminalofubiquitylatedlysines,
61
but this was not conﬁrmed by others.
60,62
2.5. Summary
Three diﬀerent methodologies are used in the ﬁeld to purify
ubiquitin and UBL target proteins, including protein tagging,
speciﬁc traps, and direct immunoprecipitation. Tagged forms of
ubiquitin and UBLs are extensively used. They enable the
puriﬁcation of target proteins in an unbiased manner and are
unlikely to discrimate between modiﬁcation via single ubiquitin
or UBL entities or via diﬀerent polymeric forms. Care should be
taken to limit overexpression of these endogenous modiﬁers.
Histidinetags andbiotinylatedtagsenablethepuriﬁcationunder
fully denaturing conditions. These conditions will inactivate
ubiquitin and UBL proteases, and the copuriﬁcation of non-
covalent interactors is avoided. However, proteins that contain
endogenous histidine stretches and endogenous biotinylated
proteins will be copuriﬁed during these procedures. Epitope tags
suchasHA,FLAG,andMycalsoenableeﬃcientpuriﬁcation,but
are not compatible with fully denaturing conditions, thus allow-
ing the copuriﬁcation of noncovalent ubiquitn and UBL inter-
actors. Tandem tags are successfully employed to obtain very
pure fractions, but large tags can aﬀect the conjugation and
deconjugation rates of ubiquitin family members.
Speciﬁc traps consisting of ubiquitin and UBL binding do-
mains enable the puriﬁcation of target proteins for endogenous
ubiquitin and UBLs. Multimerized forms of these binding
domains are very potent capturing reagents, and hundreds of
target proteins can simultaneously be puriﬁed. However, these
traps are likely to discriminate between monomodiﬁcation and
modiﬁcation by speciﬁc forms of polyubiquitylation.
Endogenous ubiquitin and UBL proteins are also puriﬁed by
immunoprecipitation using antibodies against ubiquitin and
ubiquitin family members. Several antibodies are available that
recognize ubiquitin polymers in a linkage-dependent manner.
However, due to the strong conservation of ubiquitin, it is
diﬃcult to obtain high-aﬃnity antiubiquitin antibodies.
Complementary use of the available methodologies will yield
the most reliable data sets. Identiﬁcation of the ubiquitin and
UBLacceptorlysinesintargetproteinsprovidesthemostreliable
evidence for modiﬁcation and is important for functional follow-
up studies. However, it is currently challenging to obtain a good
coverage of ubiquitin and UBL sites at a systems-wide level.7927 dx.doi.org/10.1021/cr200187e |Chem. Rev. 2011, 111, 7923–7940
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TheultimategoalofubiquitinandUBLtargetproteomicswould
be to identify dynamically regulated endogenous ubiquitin and
UBL target proteins at a systems-wide level in a site-speciﬁc and
quantitative manner.
3. UBIQUITIN PROTEOMICS
3.1. Proteomic Studies Employing Tagged Ubiquitin
In 2003, a landmark paper on ubiquitin proteomics in
Saccharomyces cerevisiae was published by the laboratory of
Gygi,
63 highlighting the impact of proteomics on the ubiquitin
ﬁeld. A yeast strain engineered to express His6-tagged ubiquitin
as the only source of ubiquitin was used for large-scale puriﬁca-
tion of ubiquitylated proteins under denaturing conditions.
Shotgun sequencing identiﬁed 1075 potential ubiquitin sub-
strates, indicating a broad impact of ubiquitin on all cellular
processes. Similar puriﬁcation approaches were used in subse-
quent studies using diﬀerent aﬃnity tags.
52,53,64 68
Anelegant virtualimmunoblotmethod waslaterdevelopedto
validate this extensive list of potential ubiquitin substrates.
62
Puriﬁed ubiquitylated proteins and total cell lysates were size-
separatedbyone-dimensionalSDS—polyacrylamidegelelectro-
phoresis (PAGE), and the gel was sliced in small gel bands and
analyzedbymassspectrometry.Thedistributionsoftheproteins
in the gel slices in both samples were compared to verify shifts in
the gel position that could be accounted for by ubiquitylation.
Despite the use of denaturing conditions, only ∼30% of the
potential ubiquitin conjugates were conﬁrmed by this method,
indicating the copuriﬁcation of large amounts of nonmodiﬁed
proteins with His6 ubiquitin and illustrating the problem of
distinguishing between covalently modiﬁed ubiquitin target
proteins and contaminants.
3.2. Ubiquitin Binding Domains
Over 250 proteins have been identiﬁed that contain ubiquitin
bindingdomains(UBDs).
24,25,54 56Theseproteinsbindubiqui-
tylated proteins and ubiquitin-like domains in proteins. Recom-
binant UBD-containing proteins can be used to identify the
ubiquitylated proteins that are regulated by these proteins.
Controls that contain mutations in the UBD domain can be
included to distinguish ubiquitin-dependent interactions from
ubiquitin-independent interactions.
Moreover, recombinant UBDs are great tools for purifying
ubiquitylated proteins in general, but they have intrinsic limita-
tions since they will likely interact with subsets of ubiquitylated
proteins. Furthermore, they usually have a relatively low aﬃnity
for ubiquitylated proteins. The S5a (Rpn10) subunit of the 26S
proteasome is a useful tool and binds to polyubiquitin chains that
consistofatleastfourubiquitinmoieties.GlutathioneS-transferase
(GST) S5a was used by Tan et al. to purify ubiquitylated
proteins from liver cells, and 83 potential ubiquitin targets were
identiﬁed. In 17 substrates ubiquitylation sites were identiﬁed.
69
Arabidopsis thaliana S5a coupled toGST and a double ubiquitin-
associated domain (UBA) from AtUBP14 coupled to GST were
usedtopurifyandidentifyatotalof294potentialubiquitintarget
proteins in Arabidopsis cell suspension cultures.
70 An elegant study
on S5a substrates in S. cerevisiae was published by Mayor et al.
71 In
this study, ubiquitin conjugates were puriﬁed in a two-step process
usingRad23-Dsk2resinandHis6 ubiquitinpuriﬁcationusingNi
2+
beads. Quantitative proteomics was employed using
15Nl a b e l i n g
to compare the ubiquitin substrates in wild-type cells and cells
deﬁcient in S5a. Of the 225 ubiquitin proteasome system sub-
strates, 27% were degraded in an S5a-dependent manner.
Recently, multimerized UBDs were shown to display up to a
1000-fold increase in aﬃnity for ubiquitin, and these so-called
tandem ubiquitin binding entities (TUBEs) now enable the
puriﬁcation of ubiquitylated proteins from primary tissues.
72
Conveniently, TUBEs protect ubiquitylated proteins from deu-




between diﬀerent species, recombinant ubiquitin is a suboptimal
antigen.Oneofthemostfrequentlyusedanti-ubiquitinantibodiesis
the monoclonal antibody FK2. Lysates can be prepared in denatur-
ingbuﬀerstoinactivateproteasesandtheproteasome,butbuﬀers
need to be diluted to milder conditions to enable immunopur-
iﬁcations. The use of partly renatured proteins increases the risk
ofcopurifyingubiquitininteractorstogetherwithubiquitintarget




74 345 distinct proteins were identiﬁed that
were enriched by FK2 from HEK293T cells under stringent
conditions. Eighteen ubiquitylation sites were found, including
ubiquitylation sites on lysines 6, 11, 33, 48, and 63 of ubiquitin,




A total of 1175 proteins were identiﬁed in FK2 immunoprecipi-
tatesfromHeLacells.Inaddition,582proteinswereidentiﬁedin
FLAG His6 ubiquitin precipitates to reach a total nonredun-
dant set of 1472 potential ubiquitin target proteins. SILAC
technologywasusedtostudyEGF-inducedalterationsinprotein
ubiquitylation, and 265 EGF-responsive target proteins were
identiﬁed, including endocytic proteins, ubiquitylating and deu-
biquitylating enzymes, transporters, and proteins involved in
translation and transcription. The number of ubiquitylation sites
identiﬁedinthisstudy,31,wasstillmodestcomparedtothelarge
total number of target proteins. Interestingly, EphA2 was identi-
ﬁedas a novel, downstreamubiquitylated target of the epidermal
growth factor receptor that is critical for proliferation and cell
migration in response to EGF.
3.4. Site-Specific Ubiquitin Proteomics
Similar to phosphoproteomics
37 and acetylation proteomics,
48
site-speciﬁc identiﬁcation of ubiquitin targets is the most reliable
method for the detection of covalently modiﬁed proteins. In the
study by Peng et al.,
63 110 ubiquitylation sites were identiﬁed.
Recently, a monoclonal antibody was generated that speciﬁ-




ubiquitylated fragments from target proteins and the identiﬁca-
tion of 374 diglycine-modiﬁed lysines on 236 ubiquitylated
proteins. Naturally occurring internal diglycines in proteins were
not recognized by the antibody, indicating its speciﬁcity. This is
an important step toward systems-wide identiﬁcation of ubiqui-
tin targets in a site-speciﬁc manner.
Themajorityoftheidentiﬁedtargetproteinsarelocatedinthe
cytoplasm, and 28.7% of the ubiquitin targets are nuclear.
Furthermore, ubiquitylation sites were identiﬁed in proteins that
localize in mitochondria, the endoplasmic reticulum, the Golgi,
andtheplasmamembrane.Nearlyhalfofthetargetsareinvolved7928 dx.doi.org/10.1021/cr200187e |Chem. Rev. 2011, 111, 7923–7940
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in cellular metabolism and 13% in cell-cycle progression and
apoptosis. Signaling proteins represent 9.1% of the targets, and
8.3% of the targets are involved in protein traﬃcking. Ubiquity-
lated targets furthermore include structural proteins (4.4%),
components of the immune system (4.2%), and transporters of
small molecules (2.3%).
57




lysines compared to lysines in general. Interestingly, ubiquity-
latedlysinesarenotnecessarilysituatedonsitesthatarenormally
surface exposed since only 60% of the ubiquitylated lysines are
exposed, compared to 45% for lysines in general.
This site-speciﬁc manner of ubiquitin target identiﬁcation has
twosigniﬁcantdrawbackssincethetrypticfragmentsthatremain
attached to target proteins from the ubiquitin-like proteins
Nedd8 and ISG15 are also diglycines and the monoclonal
antibody that is being used to purify modiﬁed lysines is not able
to discriminate between diglycines corresponding to ubiquityla-
tion, Neddylation, or ISGylation. To circumvent this problem
and to increase the yield of the procedure, His6 ubiquitin was
employed for prepuriﬁcation prior to immunoprecipitation of
the ubiquitylation sites. Furthermore, the antibody fails to recog-
nizeubiquitylatedcysteines,
76andtheantibodymightnotcapture
the full ubiquitylated proteome due to the nature of the antigen
that was used to generate this antibody.
A TUBE puriﬁcation strategy was used by Shi et al. to purify
endogenous ubiquitin conjugates.
77 They identiﬁed 293 ubiqui-
tylationsiteson223substrates,including33mitochondrialproteins,
suggesting an important role for ubiquitin in mitochondria. KxLxD
was identiﬁed as an infrequent putative ubiquitylation motif.
Recently, Nielsen and co-workers reported the currently largest
ubiquitinproteomicsstudywithatotalof5756putativeubiquitin
substrates.
78 Proteins conjugated to Strep HA ubiquitin were
puriﬁed from U2OS and HEK293T cells stably expressing tandem
tagged ubiquitin. Mass spectrometry was performed using an
LTQOrbitrapVelos.Bothprecursorandfragmentpeptideswere
analyzed in the orbitrap, resulting in high mass accuracy and
optimalspectrumquality.Theincreasedfragmentationeﬃciency





Interestingly, N-terminal substrate ubiquitylation was not ob-
served, indicating that this is a rare event. Alignments of protein
regions ﬂanking ubiquitylated lysines did not reveal unique
sequencefeatures.However,itremainstobedeterminedwhether
speciﬁcenzymesrecognizespeciﬁc ubiquitylationsites.Ubiquitin
preferably targeted lysine residues located in ordered helical
regions that were surrounded by smaller and positively charged
amino acids. Low conservation of ubiquitylation sites between
eukaryotic species was observed, indicative of promiscuity of
ubiquitylation at the site level. Ubiquitin was furthermore found
to form mixed chains with the ubiquitin-like proteins SUMO-1,
SUMO-2, SUMO-3, and Atg12.
In addition to these large-scale projects, mass spectrometry
has also been extensively used to identify ubiquitylation sites on
individual target proteins. A few examples are the ubiquitylation
sites on the X-linked inhibitor of apoptosis protein,
81 TRAF1,
82
histone variant macro H2A1.2 and histone H2A,
83 and check-
point with forkhead-associated and RING protein Chfr.
84
3.5. Ubiquitin Chains
Ubiquitin contains seven internal lysines (K6, K11, K27, K29,
K33, K48, and K63), and all lysines participate in ubiquitin chain
formation as ﬁrst demonstrated by mass spectrometry.
63 E2
enzymes play an important role in chain assembly and regulate
chain topology.
85 Lysine 48-linked ubiquitin chains were pre-
viously identiﬁed as the ubiquitin polymer that is required to
targetproteinsfordegradationbytheproteasome.
86,87 Lysine48
of ubiquitin is essential for cell viability since a K48R mutant of
ubiquitin as the single source of ubiquitin in S. cerevisiae causes
cell-cycle arrest.
88 Subsequently, lysine 63-linked chains were
shown to play a role in DNA repair,
89 as activators of the NFkB
regulating kinase complex IKK (IkB kinase),
90 and in antiviral
innate immunity.
91 Lysine 6-linked ubiquitin chains are gener-
ated by the complex consisting of Breast cancer type 1 suscept-
ibility protein (BRCA1) and BRCA1-associated RING domain
protein 1 (BARD1),
92 94 and lysine 11-linked ubiquitin chains
are generated by the anaphase-promoting complex/cyclosome




component NEMO (NFkB essential modulator) is regulated via
linearubiquitinchains.
98,99 Linear ubiquitin chains are assembled
bythelinearubiquitinchainassemblycomplex(LUBAC),which
contains the RING family members RNF31 and RNF54,
100
and Sharpin.
101 103 Mass spectrometric evidence to support
head-to-taillinearubiquitinchainshasrecentlybeenprovided.
101 103




104 Complex ubiquitin chain topology on in
vitroubiquitylatedcyclinB1waspreviouslyreported,
105andmixed
chain formation also occurs in cells.
106 However, complex forked
chains are poorly degraded by the proteasome, and the generation
Figure 3. Site-speciﬁc ubiquitin puriﬁcation methodology. A monoclonal antibody is available that recognizes diglycine motifs attached to lysines in
targetproteins.Thesediglycinesbecomeavailableupondigestionofubiquitinconjugateswithtrypsin.Afterdigestion,ubiquitylationsitesarepuriﬁedby
immunoprecipitation and analyzed by MS. Note that the C-terminal tryptic peptides from ubiquitin and the UBLs Nedd8 and ISG15 are identical and
that a pre-puriﬁcation step is therefore required.7929 dx.doi.org/10.1021/cr200187e |Chem. Rev. 2011, 111, 7923–7940
Chemical Reviews REVIEW
of these forked chains is counteracted by the S5a protein via its
ubiquitin interaction motif (UIM) domain.
107 Interestingly, all
ubiquitin chains with the exception of lysine 63-linked chains were
shownbyAQUAtoaccumulateuponinhibitionoftheproteasome,
indicating that they all play a role in protein degradation.
58
Consistently, mutant ubiquitin with lysine 48 as the single lysine
available for chain formation cannot support yeast viability.
58




neurons, ubiquitin accumulates in inclusion bodies also contain-
ing polyglutamine-expanded huntingtin protein characteristic for
HD. Mass spectrometry based methods were used to reveal that
polyubiquitin chains, including lysine 48-, lysine 63-, and lysine
11-linked chains, accumulated early in brains from a transgenic
HD mouse model, brains from a knock-in mouse model of HD, and
in brains from human HD patients
109 a n da l s oi nb r a i n sf r o m
Alzheimer’sdiseasepatients.
110Theseresultsimplythataccumulation
of these ubiquitin chains could be used as biomarkers of the disease.
3.6. Wiring of the Ubiquitin System
A signiﬁcant percentage of eukaryotic genomes are dedicated
to the ubiquitin system, including nearly 100 diﬀerent ubiquitin
proteases, 250 ubiquitin receptors, and over 600 components of
E3 ligases in humans. We are limited in our understanding of the
wiring of this system, and unbiased proteome-wide studies are
needed to establish the identity of the single targets or multiple
targets that are being regulated by diﬀerent proteases, E3 enzymes,
and noncovalent ubiquitin binders. Quantitative proteomics
methodologies are particularly powerful tools
26,28 and can be
used to identify these targets by comparing ubiquitylated pro-
teinsin the presence and absence of speciﬁc proteases, ligases, or
receptors (Figure 4). Inactivation of speciﬁc proteases or ligases
can be carried out by RNAi or by speciﬁc chemical inhibitors.
Whethertheidentiﬁedproteinsaredirecttargetsorareindirectly
regulated by these proteases and ligases can subsequently be
establishedusinginvitroassayscontainingrecombinantenzymes
and substrates.
The ﬁrst study that reported on the identiﬁcation of a speciﬁc
ubiquitin ligase for a target protein by mass spectrometry was
publishedin1998andidentiﬁedtheE3ligaseF-boxandWDrepeats
protein β-TrCP as a regulator of the NFkB inhibitor IkBα.
111 In
vitro experiments conﬁrmed the ubiquitylation of IkBα by β-TrCP.
Anotherimportantubiquitintargetisthetumorsuppressorp53.
112
Critical regulators are the RING ﬁnger proteins Mdm2
113 117
Figure 4. Quantitative proteomics strategy to identify target proteins for ubiquitin E3 enzymes. SILAC technology is used for diﬀerential labeling of
cellstogeneratetwodistinctpools.UsingRNAiorspeciﬁcinhibitors,E3enzymescanbeinactivated.Targetproteinsthatareregulatedbytheindicated
E3enzymecanbeidentiﬁedbypurifyingubiquitinfrombothpoolsofcellsandanalyzingthepuriﬁedsamplesbymassspectrometry.DecreasesinSILAC
ratios for speciﬁc proteins upon E3 inactivation will reveal potential target proteins for this E3 enzyme. Similar strategies can be used to identify target
proteins for ubiquitin proteases or ubiquitin proteome dynamics in response to speciﬁc stimuli. A third SILAC pool can be added as a negative control.
Alternative quantitative proteomics methodologies are also available.7930 dx.doi.org/10.1021/cr200187e |Chem. Rev. 2011, 111, 7923–7940
Chemical Reviews REVIEW
and MdmX/4.




121 and ARF-binding protein 1 (ARF-BP1).
122
Tosearchforp53regulatorsinanunbiasedmanner, Barton and
colleagues employed a mouse model expressing a TAP-tagged
p53 protein.
123Puriﬁedp53proteincomplexeswereanalyzed by
mass spectrometry and revealed MDM2 and a novel ubiquitin
ligase, the TRIM24 (RNF82) protein, as p53 regulators.
Thepotentialoftheseapproachesisfurthermoreillustratedby
a quantitative proteomics study of the orphan F box protein
Mdm30p,
124aproteinthatregulatesmitochondrialmorphology.
Ubiquitylated proteins were puriﬁed from yeast cells overexpres-
sing Mdm30pand control cells, using a clever two-step ubiquitin
aﬃnity puriﬁcation method.
125 Cells that express both His8 
ubiquitin and FLAG ubiquitin were used, and poly- and multi-
ubiquitylated proteins were selectively isolated by purifying
His8 ubiquitin under denaturing conditions followed by an anti-
FLAG immunoprecipitation. Eluates were analyzed by mass spec-
trometry to reveal the mitochondrial outer membrane protein
Mdm34p as a target protein that is ubiquitylated by Mdm30p.
Other E3 ligase target protein connections that were de-
tected by mass spectrometry include BRCA1/BARD1 and
nucleophosmin/B23,
126 the cellular inhibitor of apoptosis 2
and TRAF1,
82 the F-box protein Grr1 and nitrogen permease
regulator 2,
127 the RING-domain-containing K5 modulator of
immune recognition from Kaposi sarcoma-associated herpes-
virus and activated leukocyte cell adhesion molecule,
128 the
interferon inducible E3 ligase Ro52 and interferon regulatory
factor IRF8,
129 muscle RING-ﬁnger protein-1 (MuRF1) and
muscle-type creatine kinase, myosin binding protein C, and
myosin light chains 1 and 2,
130,131 RN181 and platelet integrin
α(IIb)β3,
132 the testis-speciﬁc HECT-domain E3 LASU1 and
histones, and
133 new substrates for the MARCH9 transmem-
brane E3 ligase
133 and for the APC/C complex.
134
Proteomics was also inﬂuentialto connect ubiquitin proteases
and ubiquitin target proteins: USP7 regulates the mitotic check-
point protein Chfr,
135 OTUB1 regulates estrogen receptor-α,
136
and the familial cylindromatosis tumor suppressor CYLD deu-
biquitylates Dishevelled to regulate Wnt signaling.
137
3.7. Protein Complexes in the Ubiquitin System
Mass spectrometry is a particularly powerful tool to identify
ubiquitin target proteins, but has also been extensively used for
other purposes in the ubiquitin ﬁeld. Many components of the
ubiquitin conjugating and deconjugating machinery are multi-
protein complexes that can be readily studied by mass spectro-
metry.Entryintoanaphaseandexitfrommitosisismediatedbya
very large ubiquitin E3 ligase complex, the APC/C complex.
138
The composition of this complex was ﬁrst revealed by mass
spectrometry in yeast and shown to contain at least 12 subunits,
including the RING-ﬁnger protein Apc11 and the Cullin
Apc2.
139 In mammals, the complex consists of the core complex
Apc1 8,Apc10,Apc11,Apc13,Cdc26(Apc12),andtheadaptor
subunits Cdc20 and Cdh1, which mediate the interaction with
substrates.
138 Recently, the small novel component APC16 was
identiﬁed.
140,141
The complex consisting of DNA damage-binding protein 1
(DDB1), Cullin 4 (Cul4), and RBX1/ROC1 (RNF75) is a
smaller Cullin E3 complex which regulates DNA repair, replica-
tion, and transcription and can be employed by viruses. A novel
family of WD40-repeat-containing proteins were identiﬁed as
substrate-recruiting modules of this E3 by protein complex
puriﬁcation and mass spectrometry.
142 T h e s es u b s t r a t er e c r u i -
tersdirectlybindtotheDDB1double-propellerfold,revealing
a novel mechanism underlying the substrate recruitment by
this important E3 complex.
Another interesting study involves the ATP-dependent chaper-
one p97, a critical regulator of endoplasmic reticulum associated
proteindegradation(ERAD).
143Proteomicswasemployedtoreveal
an important novel function for p97 in ubiquitin proteasome-
mediatedturnoverofsolubleproteins.
144Asetofeightubiquitin-
like module UBX-domain-containing proteins was identiﬁed by
proteomics as p97 interactors, and subsequently, all 13 UBX
proteins were shown to bind p97. UBX proteins are furthermore
connectedtoatleast38ubiquitinE3ligases,andasubsetofUBX
proteins can directly bind to ubiquitylated proteins via UBA
domains to connect p97 to ubiquitin-mediated protein degrada-
tion by the proteasome.
E3 ligases and ubiquitin proteases interact with partner proteins
to carry out their functions,
18 and these protein protein inter-
actions are eﬃciently revealed by mass spectrometric analysis of
puriﬁed protein complexes. Recently, the protein product of the
candidate oncogene TSPYL5 was identiﬁed as a partner and
inhibitorofUSP7,resultinginincreasedp53ubiquitylation.
145In
a systematic approach, 75 human Dubs were epitope tagged and
puriﬁed from cells stably expressing low amounts of these
proteases.
146 A total of 774 candidate interacting proteins were
identiﬁed, and connections with biological pathways were iden-
tiﬁed for many previously unstudied Dubs. Interestingly, this
studyrevealed that 26 ubiquitin proteases interact withubiquitin






149 and the USP19 KPC1 (RNF123) pair.
150
3.8. Summary
Tagged forms of ubiquitin, ubiquitin traps, and anti-ubiquitin
antibodies are used in the ﬁeld to purify ubiquitin conjugates.
Advantages and disadvantages of these methodologies are sum-
marized in section 2.5. Site-speciﬁc identiﬁcation of ubiquitin
conjugates was recently enabled by a monoclonal antibody
directed against diglycines attached to the ε-amino groups of
lysines.
57 This antibody is unfortunately unable to discriminate
between ubiquitylation sites and modiﬁcation sites of the UBL
proteins ISG15 and Nedd8. It is however not necessary to use this
monoclonal antibody to obtain site-speciﬁc insight into protein
ubiquitylation, since the largest site-speciﬁc study was performed by
analyzing a complex mixture of ubiquitin conjugates.
78 In total 753
ubiquitylation sites were identiﬁed in this study. Interestingly, no
consensus site for ubiquitylation could be identiﬁed in this data set.
Improvements in site-speciﬁc methodologies are expected to enable
increases in the coverage of ubiquitylation sites. This is needed to
studyubiquitylationdynamicsinresponsetodiﬀerentstimuliandto
identify speciﬁc ubiquitin target proteins that are regulated by the
vast amounts of E2 enzymes, E3 enzymes, and ubiquitin proteases.
4. SMALL UBIQUITIN-LIKE MODIFIERS
4.1. Overview
SUMO-1wasidentiﬁedasaRanGAP1-modifyingproteinthat
targets RanGAP1 to the nuclear pore.
151 154 The SUMO family
includes three members, SUMO-1, -2, and -3, which display the
characteristic β-grasp ubiquitin fold, despite limited sequence
homologies to ubiquitin of 20%, 16%, and 16%, respectively.
4,57931 dx.doi.org/10.1021/cr200187e |Chem. Rev. 2011, 111, 7923–7940
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Mature SUMO-2 and SUMO-3 are virtually identical and diﬀer
∼50% from SUMO-1. SUMOs are frequently conjugated to
target proteins via SUMOylation consensus sites
155 and form
chains via internal SUMOylation sites.
156 158 SUMOylated
proteins interact in a noncovalent manner with other proteins
via SUMO interaction motifs (SIMs). The SUMO conjugation
cascade consists of the heterodimeric SUMO E1, the single
SUMO E2 Ube2I, previously known as Ubc9, and a limited
number of E3 enzymes, including Siz/PIAS family members,
RanBP2, Pc2, and Topors.
159,160 SUMOylation is a reversible
process; six SUMO proteases are known to remove SUMOs
from target proteins and mediate the maturation of SUMO
precursor proteins.
161,162 Ube2I-deﬁcient mouse embryos die at
the early post-implantation stage due to nuclear and chromoso-




Similar to ubiquitylation, puriﬁcation and identiﬁcation of
targetproteinsbymassspectrometryiscriticalforunderstanding
protein SUMOylation. Epitope-tagged SUMOs are extensively
used in the ﬁeld to purify SUMO conjugates. Tags that have




166 171 the Myc-tag,
164 the HA-tag,






and protein A TEV CBP.
50 Furthermore, SUMO conjugates
have been puriﬁed using anti-SUMO antibodies
177,178 or a SUMO
aﬃnitytrapbasedontheN-terminalregionfromRNF4thatcontains
four SUMO Interaction Motifs (SIMs).
179 Hundreds of potential
SUMO target proteins have been identiﬁed in these studies.
The largest functional group of SUMO targets are transcrip-
tional regulators including speciﬁc transcription factors, basal
transcription factors, chromatin remodelers, coactivators, and
corepressors. The emerging picture is that transcription factors
are frequently inhibited by SUMOylation via recruitment of
transcriptional repressors that contain SUMO interaction
motifs.
160,180 186 Furthermore, these proteomics studies have
uncoveredrolesforSUMOsinmanycellularprocesses,including
DNA repair,
187 RNA metabolism, protein transport, translation,
and replication. Quantitative proteomics was used to show that
diﬀerent SUMO family members have overlapping and distinct
sets of target proteins.
170
Most SUMO proteomics studies have been performed under
regular cell culture conditions. Interestingly, SUMO-2 conju-
gates are strongly regulated by diﬀerent stress conditions,
188
including heat shock,
50,179 and via crosstalk with the ubiquitin 
proteasome system.
168
SUMO proteases are very potent and are generally inhibited
by employing denaturing buﬀers. These buﬀers also prevent the
copuriﬁcation of non-SUMOylated proteins that interact with
SUMOylated proteins via SIMs. Several of the described tags
require partial renaturation of the denatured proteins, and this
could potentially lead to SUMO protease activity and copuriﬁca-
tion of non-SUMOylated proteins via SIMs.
4.3. Site-Specific SUMO Proteomics Approaches
The currently available methods to purify SUMOs harbor the
risks of copurifying matrix-associated contaminants and SUMO
binding proteins that interact noncovalently with SUMOylated
proteins via SIMs. Site-speciﬁc techniques that enable direct
mapping of SUMO acceptor lysines would greatly facilitate
progress in the ﬁeld. However, in contrast to phosphorylation
and acetylation, it has been virtually impossible to directly
identify SUMOylation sites in endogenous target proteins by
massspectrometry.Thishashamperedprogressintheﬁeldsince
it is clear that a considerable percentage of SUMO targets are
conjugated to SUMOs via nonconsensus sitesfor SUMOylation.
More than 40% of the published yeast SUMO conjugation sites
occur at nonconsensus lysine residues.
189
In contrast to ubiquitin, C-terminal tryptic fragments of
SUMOs are very large and give rise to complex overlapping
fragmentation spectra when analyzed by mass spectrometry.
190
The C-terminal tryptic fragments of SUMO-2 and SUMO-3 are
identical 32 amino acid peptides. The C-terminal tryptic frag-
ment of SUMO-1 is considerably smaller and is 19 amino acids
long. Several diﬀerent approaches have been used for the
identiﬁcation of SUMOylation sites. Chymotrypsin treatment
signiﬁcantly reduces the size of the C-terminal SUMO
fragment.
191 The identiﬁcation of SUMOylation sites is further-
more facilitated by introducing an artiﬁcial tryptic site through
insertion of an arginine residue.
192 It was shown that these
mutations did not alter the behavior of SUMO-1.
192,193 Related
mutants were used in HeLa cells to identify 14 SUMO-1
conjugation sites,
194 in HEK293 cells to identify 17 SUMO-3
conjugation sites,
166 and in A. thaliana to detect 17 SUMO-1
conjugation sites.
167 SUMmOn,
195 a pattern recognition tool,
has been successful in detecting peptides modiﬁed by SUMO in
vitro. We have used a targeted mass spectrometric approach
combined with the linearization of the branched peptides to
detect SUMO polymerization sites puriﬁed from cells.
156 A
database containing “linearized branched” peptides was em-
ployed by Hsiao et al. to detect SUMO-modiﬁed lysines,
177
resulting in the identiﬁcation of a single SUMO site in endogen-
ousproteinspuriﬁeddirectlyfromcellsand17sites,including8sites
Figure 5. Site-speciﬁcS U M Op u r i ﬁcation methodology. An epitope-tagged lysine-deﬁcient SUMO mutant can be used to purify and identify
SUMOylation sites. Using this methodology, SUMO conjugates are digested with endopeptidase Lys-C, which cleaves C-terminal of lysine residues.
Afterdigestion,SUMOtargetproteinsarecleaved,buttheSUMOmutantstaysintactandcanbepuriﬁedusingthetag.Thepuriﬁedsampleissubsequently
digestedwithtrypsin,whichcleavesC-terminalofarginineresiduesintheSUMOmutantandinthetargetproteinfragments.Introducinganarginineatthe
C-terminusofSUMOwillprovide convenient“QQTGG” SUMOtrypticfragmentsthatcan beidentiﬁedbymassspectrometry. “QQ” ions are generated
upon fragmentation of these puriﬁed SUMO sites and are useful as reporter ions. One example of these reporter ions is provided in Figure 6.7932 dx.doi.org/10.1021/cr200187e |Chem. Rev. 2011, 111, 7923–7940
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on the SUMO E3 ligase RanBP2, after incubation of a cellular
extract with ATP. Application of these strategies to in vivo
samples has been limited by the very high complexity of the
peptide mixture and very low abundance of SUMO conjugates.
We have recently developed a novel method to purify and
identify SUMO target proteins from cells in a site-speciﬁc
manner
157 (Figure 5). The key innovation of our strategy is
the use of a lysine-deﬁcient SUMO mutant that is resistant to
cleavage by the endopeptidase Lys-C, whereas virtually all other
proteins contain lysines and are cleaved by Lys-C. After Lys-C
treatment, intact SUMO mutants plus small fragments contain-
ing the modiﬁed lysines of target proteins are puriﬁed in a
denaturing buﬀer, which excludes the copuriﬁcation of SUMO-
interacting proteins. This results in excellent purity of the ﬁnal
sample and a very low complexity due to removal of non-
SUMOylated proteins and removal of non-SUMOylated tryptic
fragments of target proteins. A disadvantage of lysine-deﬁcient
SUMOs is that these proteins no longer form SUMO chains.
Therefore, the method is only suitable for studying mono-
SUMOylation but not for studying poly-SUMOylation. How-
ever, the level of SUMO chains in cells under non-stress
conditions appears to be very low.
50,156 In addition, peak assign-
mentwasenabledbyintroducinganarginineatposition87or90,
corresponding to arginines in S. cerevisae SUMO (SMT3) or in
ubiquitin,respectively(Figure6).Onthebasisofthe103SUMO
conjugation sites that were identiﬁed (Figure 7), we have reﬁned
the SUMOylation consensus motif to [VILMFPC]KxE.
157
Moreover, two novel SUMOylation consensus motifs were
uncovered, including the inverted SUMOylation consensus
motif [ED]xK[VILFP] and the hydrophobic-cluster SUMOyla-
tion motif (HCSM).
4.4. Summary
Tagged forms of SUMO, SUMO traps, and anti-SUMO
antibodies are used in the ﬁeld to purify SUMO conjugates.
Advantages and disadvantages of these methodologies are sum-
marized in section 2.5. Site-speciﬁc identiﬁcation of SUMOyla-
tion sites by mass spectrometry is very challenging due to the
large C-terminal tryptic tags of mammalian SUMOs. The
C-terminal tryptic tag of S. cerevisae SUMO, SMT3, is much
smaller and consists of the pentamer EQTGG. Introduction of
arginines in the C-temini of mammalian SUMOs enables the
mapping of SUMO acceptor lysines in target proteins. In the
largest study, over 100 SUMOylation sites were identiﬁed in
endogenoustargetproteinsofSUMO-2.
157Themostprominent
SUMOylation consensus site in this data set was [VILMFPC]KxE.
Site-speciﬁc methodologies will most likely be improved in the
future to increase the coverage of SUMOylation sites. This will
enable more detailed insight into SUMOylation dynamics in
response to a wide variety of diﬀerent stimuli.
5. UBIQUITIN-LIKE PROTEIN NEDD8
5.1. Overview
The Nedd8 protein has the highest homology with ubiquitin
(58% identical) of allubiquitin-like proteins and is conjugated to
target proteins via a similar enzymatic cascade including the
Nedd8-speciﬁc E1 complex UBE1C NAE1 and the E2 enzyme
UBE2M (Ubc12).
196 198 This ubiquitin family member
is an important regulator of Cullin-containing ubiquitin E3
ligases,




Figure 6. Example of a SUMOylation site identiﬁed by mass spectrometry. Lysine 497 of nucleolar protein NOP5/58 was identiﬁed as a SUMO-2
acceptorsiteusingtheSUMO-2mutantQ87R.Theidentiﬁedtrypticfragmentcontainedaphosphorylatedserineonposition502.Thedoublymodiﬁed
peptide was identiﬁed by high-resolution tandem MS using higher energy collisional dissociation. Inset: Magniﬁcation of the low mass region showing




202 205 De-Neddylation of Cullins is mediated by the
COP9 signalsome complex.
206 Recently, the dynamic architecture
oftheCullin RING ubiquitin ligase network was elucidated using
AQUA technology
29,207 and that for Cul-1 by SILAC
technology.
26,27,208 Surprisingly, these studies revealed that Ned-
dylation is not required for the interaction of Cullins and adapter
proteins. Interestingly, Neddylation is deregulated in neurodegen-
erative diseases
209,210 and cancer.
210,211 Consequently, the Nedd8
E1 inhibitor MLN4924 acts as a potent anticancer drug.
212
MLN4924 functions as a cancer therapeutic because it inhibits
Cullin RING ubiquitin ligases by blocking Cullin Neddylation.




Three proteomics studies were published on Nedd8 target




207 As expected, Cullins were detected as
prominentNedd8targets;Xirodimasetal.identiﬁedCul-1,-2,-3,
-4A, -4B, and -5,
216 Bennett et al. identiﬁed seven Cullins,
including Cul-7
207 and Jones et al. identiﬁed all eight Cullin
familymembersincludingParc.
215Jonesetal.furthermoredetec-
ted other components of Cullin-containing ubiquitin ligases,
including 12 F-box proteins, RBX1/ROC1 (RNF75) and Skp1,
and identiﬁed target proteins that play important roles in DNA
repair, transcription, and replication.
215 Bennett et al. also
identiﬁed 12 F-box proteins, S-phase kinase-associated proteins
1 and 2 (Skp1 and Skp2) and several BTB-domain-containing
proteinsandWD40-repeat-containingproteinsthatwerepresent
in FLAG HA Nedd8 IPs in an MLN4924-sensitive manner.
207
BTB-domain proteins act as substrate-speciﬁc adaptors inCul-3-
containing E3 ligase complexes.
217,218 Xirodimas et al. identiﬁed
a subset of ribosomal proteins as novel Nedd8 targets and showed
that lack of Neddylation caused ribosomal protein instability.
214
Interestingly, Jones et al. furthermore revealed for the ﬁrst time
that Nedd8 forms chains via lysines 11, 22, 48, and 60.
6. UBIQUITIN-LIKE PROTEIN ISG15
6.1. Overview
ISG15 contains two ubiquitin-like domains that are respectively
29% and 36% identical to ubiquitin. This protein was identiﬁed
more than 30 years ago as an interferon-α and -β-regulated
protein.
219 ISG15 has antiviral activity against HIV, inﬂuenza,
Sindbis, and Ebola.
220 223 Conjugation of ISG15 to target proteins
is delayed until 18 24 h after stimulation with interferon
224 due
to a delay in the induction of the E1, E2, and E3 enzymes.
225 These
enzymes have been identiﬁed as Ube1L,
226 UbcH8/Ube2L6,
227,228





229 233 The identiﬁed proteins comprise a
rather heterogeneous group containing targets from many cellular
compartments with no obvious enrichment for speciﬁc func-
tional groups. Interestingly, they include 12 interferon-induced
proteins. Important novel insight was obtained in a recent
proteomics study, showing that ISG15 conjugation is restricted
to newly synthesized proteins and includes exogenously ex-
pressedforeignproteins.
234Thus,ISG15targetsnewlytranslated
viral proteins in infected cells, and this is a cellular defense
mechanismagainstviralinfectionasIGS15modiﬁcationdisrupts
virus particle assembly. Association of the E3 ligase Herc5 with
polyribosomes explains how newly synthesized proteins are
selected. Consistenly, ISGylation of the L1 capsid protein of
papillomavirusreducesthe infectivity of the produced viruses.
234
7. OTHER UBIQUITIN-LIKE PROTEINS
7.1. Overview
Target proteins for ubiquitin-related modiﬁer 1, prokaryotic
ubiquitin-like protein, and small archaeal modiﬁer proteins have
been identiﬁed and are described in sections 7.2 7.4. Currently,









239 by an E1 enzyme Atg7,
240 and an E2 enzyme, Atg10.
241
The target for Atg8 is phosphatidylethanolamine, and conjuga-
tion involves Atg7 and the E2 enzyme Atg3.
242 Human Atg8
family members interact with at least 67 proteins, probably in a
non-covalent manner.





used by ubiquitin and ubiquitin-like proteins for covalent con-
jugation to target proteins.
7.2. Ubiquitin-Related Modifier 1
Ubiquitin-related modiﬁer 1 (Urm1) was discovered in 2000
byFurukawaetal.asaproteinshowingsequencesimilaritytothe
bacterial sulfur carriers ThiS and MoaD.
247 Characteristically,
Urm1 is a small protein of 99 amino acids with a C-terminal
diglycine motif.
248,249 In a subsequent yeast two-hybrid screen
for Urm1 interactors, the Uba4 protein, related to the ubiquitin-
activating E1 enzyme Uba1, was identiﬁed. Immunoblotting
experiments revealed Urm1 conjugates that were formed in a
Uba4-dependent manner.
250,251 Until recently, the only known
Urm1 substrate was the peroxiredoxin Ahp1.
252 Recently,
HA Urm1 conjugates were puriﬁed from HeLa cells, and 21
novel potential Urm1 target proteins were identiﬁed by mass
Figure 7. SUMOylation consensus site. Graphical representation of the local target protein context of 103 SUMO-2-conjugated lysines that were
identiﬁed using the method described in Figure 5. The SUMO-2 acceptor lysines were aligned using WebLogo. SUMOylation sites are frequently
located in the consensus motif [VILMFPC]KxE. SUMOylation consensus motifs furthermore include the inverted SUMOylation consensus motif
[ED]xK[VILFP] and HCSM. Reprinted with permission from ref 157. Copyright 2010 Elsevier.7934 dx.doi.org/10.1021/cr200187e |Chem. Rev. 2011, 111, 7923–7940
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spectrometry.
253 Four target proteins were subsequently con-
ﬁrmed, including adenylyltransferase and sulfurtransferase MOCS3
and ATP-binding domain-containing protein 3 (ATPBD3), two
proteins that function in the Urmylation pathway, and additionally
USP15andthenucleocytoplasmicshuttlingfactorcellularapoptosis
susceptibility protein. This study also conﬁrmed that Ahp1 is
conjugated to Urm1 via internal lysine residues. Urm1 has a double
function; it not only functions as a protein modiﬁer but ﬁttingly
with its similarity to bacterial sulfur carriers also acts as a sulfur
carrier in thiolation of eukaryotic tRNA.
254 257
7.3. Prokaryotic Ubiquitin-like Proteins
Searches have recently revealed a ubiquitin-like protein in
prokaryotes named prokaryotic ubiquitin-like protein.
258 PUP
was identiﬁed in Mycobacterium tuberculosis. Its structure is
intrinsically disordered,
259,260 but an α-helix is formed in PUP
uponbindingtotheproteasomalATPasesubunitMpa,revealing
binding-induced folding.
261 Subsequently, PUP is degraded
together with its target proteins.
262 These aspects are mechan-
istically diﬀerent from those of the eukaryotic ubiquitin protea-
some system. Conjugation of PUP to target proteins, PUPylation,
alsoproceedsviadistinctchemistryandinvolvesadeamidaseand
a glutamine synthetase-like ligase.
258,263 Recently, 243 candidate
PUPylation targets were identiﬁed by mass spectrometry
using thepuriﬁcation ofHis6-tagged PUP inthemodelorganism
Mycobacterium smegmatis.
264 For 41 of these protein targets,
PUP acceptor lysines were identiﬁed by mass spectrometry. Half
of these target proteins are involved in intermediary metabolism
and respiration pathways.OtheridentiﬁedPUPtargetsareinvolved
in lipid metabolism, virulence, adaptation, and detoxiﬁcation.
7.4. Small Archaeal Modifier Proteins
Archaea have long been known to express proteasomes that
are similar to eukaryotic proteasomes.
265,266 Recently, two small
archaeal modiﬁer proteins, SAMP1 and SAMP2, were identiﬁed
in the archaeon Haloferax volcanii.
267 These proteins contain
the characteristic ubiquitin β-grasp fold
267,268 and contain the
C-terminal diglycine motif. SAMPs are conjugated to target
proteins in H. volcanii. Whereas SAMP1 conjugates were
regulated by the proteasome, SAMP2 conjugates were not
degraded by the proteasome. FLAG SAMP conjugates were
immunopuriﬁed and identiﬁed by mass spectrometry, reveal-
ing that SAMPylation is part of the sulfur metabolism, stress
responses, basic transcription, translation, and DNA repli-
cation.
267 Isopeptide bonds between the ε-amino group of
lysinesintargetproteinsandtheC-terminalglycineofSAMP2
were conﬁrmed by mass spectrometry and also chain formatin
of SAMP2 via internal lysine 58. SAMPs are activated in an
ATP-dependent manner by an E1-like enzyme termed E1-like
SAMP activator (ELSA).
268 SAMPs are members of a large
superfamily that includes members from all major archaeal
lineages, indicating that ubiquitin-like protein modiﬁcation plays
an important role in archaea.
269
8. CROSSTALK BETWEEN POST-TRANSLATIONAL
MODIFICATIONS
The ultimate goal of PTM proteomics is to understand
how diﬀerent PTMs cooperatively regulate cellular pro-
cesses. Intriguing examples of PTM crosstalk and competition
have been published between ubiquitylation and other mod-
iﬁcations (Figure 8). Several examples of cross-regulation
between diﬀerent modiﬁcations are described in the next
section.
8.1. Crosstalk between Phosphorylation and Ubiquitylation
A classical example of crosstalk between phosphorylation and
ubiquitylation occurs in the NFkB signaling cascade. This
Figure 8. Crosstalk among ubiquitylation, SUMOylation, and phosphorylation. Extensive crosstalk among ubiquitylation, SUMOylation, and
phosphorylation includes the modiﬁcation of enzymatic components of the cascades. Furthermore, co-modiﬁcation occurs along with competition
forthe same lysine residues in target proteins bySUMO and ubiquitin or consecutive modiﬁcation by SUMO andubiquitin ofthe same lysine residues.
Moreover, noncovalent binding proteins add to the complexity but are not depicted here. Several examples are described in the main text.7935 dx.doi.org/10.1021/cr200187e |Chem. Rev. 2011, 111, 7923–7940
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transcription factor family consists of dimers of transcriptional
activators that can be sequestered in the cytoplasm bound to
members of the IkB family of inhibitors. Upon activation by
TNFα, IL-1β, and a large number of other stimuli,
270 the IKK
kinase complex phosphorylates IkBα on serines 32 and 36.
271
This enables docking of the ubiquitin E3 ligase complex
111
consisting of Skp1, Cul-1, Roc1, and βTrCP that ubiquitylates
IkBα on adjacent lysine residues 21 and 22, leading to the
destruction of the inhibitor protein by the proteasome and
translocation of the NFkB dimer to the nucleus to activate
transcription. Interestingly, lysine 21 of IkBα can also be
SUMOylated to protect the protein from degradation via the
ubiquitin proteasome pathway.
272 βTrCP is furthermore
responsible for the ubiquitylation of other proteins, including
β-catenin,
273 via its WD40 repeats, which bind the D-
(phospho)SGXX(phospho)S degradation motif in target pro-
teins. Many other SCF ligases are recruited to substrates in a
phosphorylation-dependent manner. Nevertheless, we are still
limited in our understanding of phosphorylation-dependent
protein ubiquitylation.
Crosstalk furthermore includes phosphorylation of many
components of the ubiquitylation machinery, including the
E1 enzyme, UbE2_J1, E3 ligases NEDD4.2, WWP1, UBR2,
UBR5, MIB2, and MYCBP2, E4 B, and ubiquitin proteases
USP31, USP39, USP42, UCH8, UCH10, UCH20, UCH24,
UCH32, UCH34, UCH37, CYLD, FAF-X, FAF-Y, and
BAP1.
43Vice versa, Xu et al.
57and Danielsen et al.
78 described
ubiquitylation of kinases and phosphatases, including cAMP-
dependent protein kinase type Iα regulatory subunit, casein
kinase II subunit α, serine/threonine-protein kinases 12,
cAMP-dependent protein kinase type Iα,j a n u sk i n a s e1 ,
AXLreceptortyrosinekinase,serine/threonine-protein kinase
SMG1, receptor-type tyrosine-protein phosphatase F, and
serine/threonine protein phosphatase 2A 65 kDa regulatory





HSF1 and HSF4b, myocyte-speciﬁc enhancer factor 2, and
erythroidtranscriptionfactorGATA-1.
274Recently,ﬁveproteins
were identiﬁed by mass spectrometry that are simultaneously
phosphorylated and SUMOylated with a preferred spacing
between the SUMOylated lysine and the phosphorylated serine
of four residues.
157 Modiﬁcation of NOP5/58 by SUMOylation
and phosphorylation is shown in Figure 6. Mutagenesis experi-
ments conﬁrmed that phosphorylation of the nucleolar pro-
tein NOP5/58 enhanced SUMOylation. Mechanistically, this
can be explained by increased binding of some phosphorylated
proteins to the SUMO E2 enzyme Ube2I.
275 Interestingly,
negatively charged residues in the negatively charged amino
acid-dependentSUMOylationmotif(NDSM)canpartlyreplace
phosphorylated serines to enhance the SUMOylation levels of
target proteins.
276
8.3. Competition between Different Lysine Modifications
Ubiquitin and UBL proteins are covalently linked to
lysines in target proteins. Since lysines are also subjected
to other modiﬁcations, including acetylation and methyla-
tion, this creates the potential for competition between diﬀer-
ent lysine modiﬁcations. Interestingly, four SUMOylated ly-
sinesinRanGAP1,bromodomain-containingprotein4,scaﬀold
attachment factor B2, and Treacle protein TCOF1
157 were
previously identiﬁed as acetylated lysines.
48 Dephosphoryla-
tion of a PDSM motif in the transcriptional regulator myocyte-
speciﬁc enhancer factor 2A was shown to regulate a switch
from SUMOylation to acetylation to control postsy-
naptic diﬀerentiation.
277 Competition between ubiquityla-
tion and acetylation appears to be a very frequent event,
with over 20% of the ubiquitin acceptor lysines also being
reported as sites of acetylation; e.g., all the ubiquitin acceptor
lysines in H2B, H3.1, and H4 were also reported to be
acetylated.
57,78
8.4. Crosstalk between SUMOylation and the Ubiquitin 
Proteasome System
Intriguingly, a subset of SUMO-2/3 conjugates are subse-
quently ubiquitylated and degraded.
168 Our proteomics study
showed that at least 10% of the SUMO-2 target proteins are
regulated via this type of crosstalk, and this is critical for SUMO-
2/3 recycling, indicating that the ubiquitin proteasome system
is an essential component of the SUMO cycle.
168 Mechanisti-
cally, this involves speciﬁc ubiquitin ligases that contain SUMO
interaction motifs that interact with SUMO in a noncovalent
manner.
278 282
9. CONCLUSIONS AND FUTURE PERSPECTIVES
Post-translational modiﬁcations of proteins are extremely
complex. Compared to the robust methodology available to
study phosphorylation and acetylation, the ubiquitin ﬁeld
is still lagging behind. Site-speciﬁci d e n t i ﬁcation of protein
ubiquitylation and ubiquitin-like modiﬁcation is still challen-
g i n g .C u rre n tl y ,t h eﬁeldis aiming todevelopnovel methods to
identify these modiﬁcations in a site-speciﬁcm a n n e r .T h e s e
enablingtechniqueswillopenupunprecedentedpossibilitiesto
decipher protein ubiquitylation and UBL modiﬁcation on a
proteome-wide scale. Furthermore, the ﬁeld will beneﬁtf r o m
improvementsinpeptidefragmentationenabledbyHCD
79and
improved sensitivity and mass accuracy of mass spectrometers
and software to deal in an automated fashion with the assign-
ment of modiﬁcation sites in peptides and quantiﬁcation to
detect changes in modiﬁcation levels.
35,36 The dissection of
crosstalkbetweendiﬀerentmodiﬁcationsat aproteome-wide level
will also be important. Searching MS/MS spectra for co-modiﬁca-
tions, including a larger number of diﬀerent modiﬁcations, is very
challenging due to the steep increase in computation time.
283
Systematic, unbiased, and proteome-wide studies on protein
ubiquitylation and UBL conjugation will strongly improve our
understandingofthesemodiﬁcationsinthenearfuture,particularly
with respect to the identiﬁcation of target proteins for the vast
numbers of ligases and proteases in the system and to identify the
targets that are dynamically regulated in response to a wide variety
of stimuli. This is furthermore relevant for the detailed under-
standing of deregulation of ubiquitin signaling in human
diseases
108,209 211,284 andfor the developmentof drugsthat target
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NOTE ADDED IN PROOF
Aftertheacceptanceofthispaper,threelandmarkpaperswere
published using monoclonal antibodies that recognize diglycine
remnants as described in ﬁgure 3, and ∼10000, ∼11000, and
∼19000 sites were identiﬁed respectively.
287 289 These results
indicate that the complexity of protein ubiquitylation could be
comparable to the complexity of protein phosphorylation and
that site-speciﬁc ubiquitylation studies at a proteome-wide level
are now feasible. Wagner et al. discovered a non-proteasomal
function for almost half of all identiﬁed diglycine sites.
288 The
paper by Kim et al. highlights that a very signiﬁcant fraction of
ubiquitin conjugates results from freshly translated proteins and
that ubiquitylation is frequently a sub-stoichiometric event.
289
Emanuele et al. and Kim et al. used this technology to identify
substrates for Cullin-RING ligases.
287,289